BioSpace· Nick Paul Taylor·· 5 hours agoPickScore64
Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
In brief
BioSpace reports that Genmab faces the 2029 expiry of Darzalex's U.S. patents, with revenue potentially falling from about $3.3 billion to near zero. This year the company must also report Phase 3 data from LiGeR-HN1 for petosemtamab and RAINFOL-02 for Rina-S, in first-line HNSCC and platinum-resistant ovarian cancer, respectively.
Why it matters
Places Genmab's three key readouts against the Darzalex 2029 patent cliff, helping readers assess whether petosemtamab, Rina-S and Epkinly can fill the roughly $3.3 billion revenue gap.
Source: BioSpace